NCT06553872View on ClinicalTrials.gov

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Pirtobrutinib

Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.

DRUG

Brexucabtagene Autoleucel

Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).

Trial Locations (3)

33136

RECRUITING

Univ of Miami - Sylvester Comprehensive Cancer Center, Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

94305

NOT_YET_RECRUITING

Stanford Cancer Center, Stanford

All Listed Sponsors
collaborator

Bankhead-Coley Florida Biomedical Research Program

UNKNOWN

collaborator

Eli Lilly and Company

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06553872 - Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Biotech Hunter | Biotech Hunter